- Date: February 14, 2019
Judit Cubedo (centre) with GlyCardial Diagnostics team members, Javier Sábado and Lola Fernández.
The 2015 CaixaImpulse selected project Apo J-Glyc, now GlyCardial Diagnostics, has recently received €1.9 million in the SME instrument phase II funding of the Horizon 2020 programme, an initiative of the European Commission. This brings public funding and soft loans raised by the company in the past year to a total of €2.4 million, with grants also obtained from the EIT Health Headstart programme and the Retos-Colaboración project from the Ministerio de Ciencia, Innovación y Universidades.
For Judit Cubedo, the company’s co-founder and CEO, the funding represents an important step in the advancement of the project, which is a spin-off from the Sant Pau Research Institute. “It is amazing and highly motivating to see that the EU trusts in our project as much as we do”, she commented.
GlyCardial Diagnostics is developing a kit for the early diagnosis of cardiac ischemia. The funds they have received will be used to carry out the clinical validation of the novel in vitro test for the early detection of cardiac ischemia, as well as to advance in the development of a fast-test for the rapid detection of its biomarker in blood samples.
“We are about to start the clinical study for the validation of the biomarker. This will be a prospective international study where we will be able to analyse the performance of our novel test in the real clinical setting”, said Judit. “We are very thankful to all our collaborators that have made project a success.”
More programme highlights
March 21, 2019
Rafael Mañez, the leader of a 2016 CaixaImpulse selected project, updates us on its progress.
March 19, 2019
Applications have officially closed for the fifth edition of the CaixaImpulse call.
February 28, 2019
IGTP researcher Antoni Matilla updates us on his 2016 CaixaImpulse selected project, and discusses the importance of bringing rare diseases to the forefront.